Many folks in healthcare have watched corticosteroids grow into household names, and meprednisone carved its own history in this landscape. Born from an era chasing safer, more targeted steroid options, meprednisone attracted interest for its profile as a synthetic glucocorticoid. Researchers in the 1960s pushed to improve upon early steroids like cortisone, striving for less mineralocorticoid action and more reliable anti-inflammatory power. The resulting molecule offered a promising alternative to prednisone, aiming to dial up the desired effects while dialing down side risks. This pursuit mirrored a period driven by chemistry and real clinical feedback from doctors and patients wrestling with long-term steroid use. By the 1970s, meprednisone attracted clinical trial support, but its journey never became as widespread as others in its class, often overshadowed by dexamethasone and prednisolone.
Meprednisone surfaces on pharmacy shelves as a prescription corticosteroid designed mainly for inflammation, immune suppression, and a slate of chronic illnesses. Most commonly seen as tablets but sometimes found in compounded topical or injectable formulations, it answers specific clinical questions for conditions where autoimmune or allergic responses flare out of control. Medical teams see its moderate potency and shorter half-life as fitting intermediate needs, bridging the gap between milder and more aggressive options. Usually, doses require careful adjustments, with close monitoring for adverse effects due to its systemic reach. The structure and use of meprednisone underscore how steroid therapy continues to balance T-cell suppression, mitigation of symptoms, and minimization of harm.
Peering beneath the label, meprednisone presents itself as a white to off-white crystalline powder. With a molecular formula of C22H28O5, it sits among other 21-carbon steroids, yet subtle changes in double bonds and side chains give it a different metabolic trajectory. It melts at around 220-224°C, remaining stable under typical storage but sensitive to excessive moisture and light. The poor water solubility shapes its oral formulations, contributing to a more consistent, slower absorption profile compared to heavily water-soluble analogs. Its lipid-friendly nature affects how it travels in the body, distributing through blood and tissues that crave fat-soluble compounds—a boon and a burden for those mindful of tissue-level steroid effects.
Labels on meprednisone products generally carry clear specs on purity, usually ninety-eight percent or higher, assuring prescribers and pharmacists of the product’s integrity. Tablets often weigh in at 4 mg or 16 mg, with excipient lists tailored for stability and patient safety. Manufacturers detail shelf life, recommended storage conditions below 30°C, and guidance against exposure to humidity. Regulatory frameworks in countries where it is approved dictate clear guidelines on batch testing, compliance certificates, and risk information covering contraindications and significant side effects. Information on blister packs, bottles, and inserts underscores the risk of abrupt discontinuation, making it clear that dosing changes should never happen quickly or without oversight.
Chemists engineer meprednisone through a semi-synthetic pathway. They typically start with parent steroids like hydrocortisone, driving selective oxidation and double-bond manipulation with reagents such as chromic acid or other strong oxidizers. The work requires tight environmental controls, constant analytical checks, and purification through chromatographic steps. Small changes in temperature or pH can skew the reaction, leading to unwanted byproducts or loss of potency. After synthesis, labs confirm structure and stereochemistry using NMR and mass spectrometry, sticking to rigorous standards that minimize human and environmental risk, given the biological potency of intermediates.
On the bench, meprednisone’s unique structure invites chemists to create derivatives and modifications to probe for better anti-inflammatory or immunosuppressive effects with fewer metabolic complications. Researchers pursue alternate oxidation states at carbon 11 or explore new esterification patterns on the side chains to shape its pharmacokinetics. These ventures offer possibilities for new prodrugs that might activate only at targeted tissue or for formulations better able to cross blood-brain or placental barriers, though each step brings its own safety hurdles and regulatory scrutiny. The pathway for conversion in the body, particularly involving hepatic enzymes, stands as a central focus for those aiming to refine its performance and limit exposure to biologically active metabolites.
While "meprednisone" stands as the international nonproprietary name (INN), pharmacists and clinicians might find the compound marketed under trade names such as Hostacortin or Mepacort. Some texts reference it by its chemical labels like 6-methylprednisone or 21-hydroxy-6-alpha-methyl-pregna-1,4-diene-3,11,20-trione, but these appear more in research and chemical supply catalogs than in scripts seen by patients. Local naming conventions diverge, especially across Europe and Asia, so awareness of synonyms proves essential in multinational research, cross-border supply, or when tracking side effect reports.
Medical teams follow strict protocols when prescribing or dispensing meprednisone. Guidelines direct careful baseline checks, with monitoring for blood sugar swings, bone density loss, and susceptibility to infections that long-term use encourages. Hospitals flag risk categories for pediatric and elderly patients, knowing cumulative dose impacts height, growth, and injury healing—especially relevant in those with fragile bones or immune function. Pharmacists and nurses counsel patients to take tablets with food to buffer stomach irritation and underline the importance of tapering schedules. In industrial settings, handling dry powder or large quantities means donning gloves, face masks, and ensuring proper ventilation to avoid accidental inhalation or skin exposure—reflecting the fact that even small doses can have outsized hormonal effects.
Doctors turn to meprednisone for stubborn inflammatory conditions—including rheumatoid arthritis, asthma, and severe allergies—where traditional options fall short or introduce unwanted mineralocorticoid side effects. It finds use in maintenance therapy for autoimmune disorders, often in conjunction with disease-modifying agents to provide symptom control during flare-ups. In some hospital protocols, specialists tap meprednisone as a bridge therapy to other immunosuppressants, capitalizing on its moderate duration of effect. Less often, off-label uses pop up for rare syndromes or in veterinary settings, reflecting experience-driven trust in its tolerability profile for certain populations.
Modern research on meprednisone explores how tweaks to its structure might yield new drugs with more targeted action and fewer off-target effects. Investigators employ high-throughput screening to assess binding affinity for glucocorticoid receptors, comparing results with better-known steroids. Studies probe genetic factors influencing metabolism, aiming to design more patient-specific regimens—a step forward for personalized medicine. Academic labs and industry sponsors alike watch for opportunities to cut down glucocorticoid resistance, a growing concern in treatment-experienced populations. Papers regularly report new analogs, hoping to solve old problems like Cushingoid side effects or immunosuppression-linked infections.
Meprednisone’s impact on the human body receives close scrutiny in toxicity research. Animal trials and cell studies flag potential for adrenal suppression, growth retardation, and metabolic complications at high or prolonged doses. Researchers track markers in blood and tissues for early signs of osteoporosis, hepatic enzyme induction, and hyperglycemia, striving to draw clearer lines for where benefit outweighs risk. Long-term human surveillance studies gather safety data, focusing on infection rates and the cascade of hormonal disruptions that even small steroid dosages can spark. Regulatory agencies look to these results before green-lighting broad indications or new applications, always erring on the side of minimizing harm across diverse populations.
Future paths for meprednisone research and use stand shaped by the broader drive to make steroid therapy safer and more selective. Advances in drug delivery—such as nano-formulations or tissue-selective prodrugs—promise to put medication where it’s needed while sparing the rest of the body. As researchers unlock more genetic and metabolic data on patients, the doors to precise, tailored dosing regimens swing open wider. Biotechnology firms keep an eye out for ways to swap out traditional steroids with newer molecules that maintain effectiveness without so many collateral effects on sugar metabolism or bone health. Interest keeps building for combined therapies linking meprednisone with biologics or small molecules for autoimmune diseases, aiming for better disease control at lower steroid exposures. The lessons learned from decades of meprednisone use press both researchers and doctors to rethink old habits and reach for safer, sustainable therapies as technology catches up with medical ambition.
Doctors sometimes turn to Meprednisone for folks dealing with inflammation-linked conditions. This medication comes from the family of synthetic corticosteroids, which work a lot like natural hormones your body already makes. Steroids like this have a long track record—rheumatologists and allergy specialists often keep them close at hand for a reason.
The main job Meprednisone takes on is calming the immune system. That means it can cut down swelling, redness, and pain, making life a little easier for people facing autoimmune bumps in the road or tough allergies. Autoimmune diseases cover a broad swath, including things like rheumatoid arthritis, lupus, and sometimes severe asthma. With inflammation at the core of these problems, putting the fire out helps people function better day to day.
In my own orbit, a close family friend faced months of nagging joint pain and stiffness before finally getting a diagnosis: polymyalgia rheumatica. The flares could get so bad she couldn’t tie her own shoes. Meprednisone, given by her doctor, made a night-and-day difference. After a couple days, her mornings no longer started with dread.
Stories like hers highlight what’s at stake with autoimmune flare-ups: a steep drop in quality of life, missed work, emotional strain. Even kids facing allergic rashes or adults under attack from their own immune systems sometimes get a shot at feeling normal again, thanks to medications like this.
Steroids come with baggage. Every doctor I know takes the side effects seriously. Longer courses or big doses can lead to muscle weakness, bone thinning, higher blood sugar, or trouble fighting off infections. Too many people—usually folks forced to take steroids for long stretches—end up facing these risks. Some deal with mood swings and weight gain. Appetite rarely comes under control with steroids on board.
I watched another friend battle weight creep and bruises during a years-long run on corticosteroids for kidney trouble. For her, relief from inflammation always came with trade-offs. Not everyone wants to share their struggles with side effects, but they run deep. This isn’t anyone’s first choice. Doctors routinely monitor patients with regular bloodwork and check-ins. Smart prescribing matters—in my experience, cautious use with clear goals and a solid plan for tapering does more good than harm.
Steroids sparked a revolution fifty years ago, changing lives for people with diseases that were once totally crippling. Yet medicine keeps moving. More treatments keep popping up—drugs that focus on narrower targets inside the immune system. Sometimes, these newer options allow patients to drop their steroid dose or stop steroids altogether.
Younger rheumatologists often talk with patients about new medications, and for many, those options mean a life with fewer steroid side effects. Still, Meprednisone has a real place. If a patient’s asthma attack blows up or their joint pain takes over, a quick, targeted burst of this medication still beats the alternatives.
In the end, the best results come from teamwork—patient, doctor, pharmacist all weighing risks, symptoms, and goals. Medications like Meprednisone give doctors a fighting chance at calming fierce inflammation. The trick lies in using them wisely, learning from years of experience, and always looking out for the person behind the prescription.
Meprednisone works as a corticosteroid. Doctors prescribe it for conditions like inflammatory diseases, allergic reactions, and autoimmune flare-ups. Inflammation gets calmed down quickly, and symptoms like swelling, redness, and itching tend to fade. The relief is real—especially during a bad flare. People going through difficult illnesses sometimes find that life looks a lot more manageable once the medication starts working.
Family members in my own life have relied on steroids like meprednisone amid bad asthma attacks and chronic conditions such as lupus. The difference between feeling like you can’t breathe and finally catching your breath is unforgettable. Still, taking a corticosteroid isn’t a casual decision. Side effects line up alongside the benefits. That’s not something you want to brush aside. In our experience, skipping the doctor’s instructions or stopping too soon brought on setbacks and stronger symptoms later. We learned to value clear advice and stick to the prescribed plan no matter how much better things seemed to get after a dose or two.
Doctors usually set out a daily dose, sometimes split into several small pills. Swallowing them whole with food prevents a sour stomach. Most providers prefer it if doses line up with breakfast or early in the day—nobody wants to wrestle with insomnia on top of everything else. Setting an alarm or a reminder on the phone goes a long way in keeping things on track. Forgetting doses or playing catch-up can throw your system for a loop.
If someone feels tempted to quit because side effects like mood swings or trouble sleeping kick in, it’s best to call the doctor. I’ve seen folks tempted to just stop. That opens up risk for withdrawal symptoms or even a flare of whatever condition led to using meprednisone in the first place. A doctor-guided taper is safer than going cold turkey.
Meprednisone sometimes brings side effects: mood swings, insomnia, high blood sugar, and weight gain. Prolonged courses raise the risk for bone loss or infections. That’s why doctors often call for the lowest dose that works, and for the shortest stretch possible. Keeping in touch about anxiety, new weakness, or sudden infection makes a difference. In my family, one member needed a calcium and vitamin D supplement to keep bones healthy through a longer stint.
Anyone stuck with a longer prescription should keep extra close tabs on overall health. Regular check-ups, blood work, and even blood sugar testing sometimes join the routine. Eating a balanced diet, getting exercise, and keeping up with vaccines holds up the body’s defenses while the steroids do their job. I’ve seen that doctors will shift folks off meprednisone in favor of gentler medications whenever possible. That can take patience—sometimes months of trying out different options.
People do best with meprednisone when they keep the lines of communication wide open with their medical team. No one medication works the same for everyone, so reporting changes in mood, sleep, or symptoms really helps the doctor adjust things in a timely way. Sticking to a plan, asking questions, and not making sudden changes on your own keeps complications at bay. I’ve watched loved ones move from confusion and frustration to control and comfort—step by step, with support and honest discussion.
Meprednisone lands on pharmacy shelves as a corticosteroid, usually tackling inflammation, allergies, or autoimmune flare-ups. Folks like me who’ve spent time helping friends and family wade through prescriptions know that no steroid comes without tradeoffs. Common as they are, these drugs move through the whole body, not just the sore joint or inflamed gut. This means all sorts of side effects can tag along, some manageable, others that drop a patient flat on the couch with fatigue or worry.
Talk to someone on meprednisone, and the conversation drifts to issues that don’t show up on prescription leaflets right away. Weight gain comes up at the dinner table. Eyes open wider over a bowl of ice cream when moon face — round cheeks — suddenly appears in family photos. A cousin of mine who took it for a rash said she struggled with sleep, sometimes lying awake for hours with a racing mind. Sleep troubles and changes in appetite really pull at daily life, not to mention the mood swings that sneak in and surprise loved ones. Family dynamics feel it. Relationships absorb the frustration.
Then there are the bathroom visits. Stomach aches and an uneasy gut can make everyday outings difficult. Sports and favorite foods sometimes slip off the radar for a while. This isn’t just about comfort — the body’s defenses drop. Simple colds go on and on, turning into sinus or chest infections. Even wounds heal slower, which matters for anyone gardening or supervising rough-and-tumble kids.
The longer someone stays on meprednisone, the more risks pile up. The biggest spotlight shines on blood sugar swings. Doctors see this across the board, especially in those already at risk for diabetes. After my dad used corticosteroids for chronic pain, he needed constant blood tests because steroids can nudge sugar out of normal ranges — and diabetes doesn’t give up ground easily.
Blood pressure numbers can also drift too high. The risk grows quietly with each refill. Steroids even thin out bones if used long enough, raising the chances of fractures. It’s tough to explain that invisible risk to teenagers with Crohn’s who want to play sports but later worry about hurting their wrists or ankles.
People overlook emotional fallout, but for many patients, anxiety, agitation, or depression set in. My neighbor, a tough guy by any standard, admitted he felt jumpy and down after a few weeks of treatment. In rare cases, folks can even slip into confusion or hallucinations. For seniors or people battling other health stuff, this becomes a real struggle.
Open, honest talks with doctors change lives for steroid users. Healthcare teams know that regular check-ins help spot side effects before they explode into real harm. Bloodwork, bone scans, and even basic heart checks keep surprises to a minimum. Most clinics urge patients to avoid stopping meprednisone suddenly since that can rock adrenal function.
Having an action plan helps. Patients jot down symptoms, ask pharmacists about interactions, and sometimes bring family or friends to appointments. Nutrition shifts also make a difference: more calcium and vitamin D, less salt and sugar. Regular walks around the block counter bone thinning and the blues.
More folks should know that every side effect deserves attention, no matter how minor it sounds in medical papers. Practical solutions, not just statistics, matter most to people trying to live life with fewer setbacks. Taking notes on what changes, talking out worries, and trusting the care team all work better than hiding side effects out of embarrassment or frustration. Facing them together raises the odds of finding balance, even with challenging medications like meprednisone.
Doctors sometimes prescribe meprednisone for its anti-inflammatory punch. Many people dealing with autoimmune flare-ups, stubborn asthma, or skin issues depend on it. It's easy to forget that this medicine can cause problems when it teams up with other drugs, yet that’s where real challenges begin.
Steroids like meprednisone tend to interact with a lot of medicines. Think of it less like a solo act and more like a band where every member affects the sound. Adding another medicine changes the results. Blood thinners, certain vaccines, antibiotics, seizure medications, and antifungals can lead to serious side effects when combined with steroids.
Blood thinners, including warfarin, need special attention. Mixing them with steroids can surprisingly bump up bleeding risk. Doctors run more blood tests and check for bruising. I once saw a patient with a bruise that didn't heal, and only after looking back at their prescribed list did we realize that meprednisone had nudged the problem along. Even something as simple as aspirin or NSAIDs (common painkillers) can cause stomach ulcers if used with steroids.
Vaccines work differently in people on meprednisone or other corticosteroids. The body's defense system sits on the bench while steroids do their thing. Live vaccines, such as measles-mumps-rubella or the varicella shot, risk causing real infection rather than protection. Most vaccination specialists will ask how long you've been on steroids and adjust their recommendations or delay shots as needed.
Antibiotics and antifungals, specifically drugs like erythromycin, rifampin, or ketoconazole, complicate matters. Some increase the strength of steroids in the body, almost like turning up the volume without noticing. Others do the opposite and leave you less protected against inflammation. Epilepsy drugs, such as phenytoin or carbamazepine, often weaken the effect of steroids, sometimes forcing doctors to raise the dose just to keep symptoms calm.
Adding over-the-counter treatments, herbal products, or certain dietary supplements into the mix raises more red flags. St. John’s Wort is infamous for messing up steroid metabolism, sometimes leaving patients with unexpected symptoms. People with diabetes should watch for higher blood sugar readings, since steroids tend to push those numbers up and insulin or oral diabetes medication doses may not be enough without changes.
Older adults who take meprednisone plus blood pressure medicine or heart rhythm drugs face higher risks of potassium trouble. Low potassium causes muscle weakness, and in severe cases, abnormal heart beats. Potassium levels can drop dangerously if steroids combine with drugs like furosemide or digoxin.
To avoid surprises, talking with a pharmacist every time the prescription list changes pays off. Reporting all drugs, vitamins, herbs, or supplements you take will help catch bad combinations early. Most electronic prescribing tools now warn about interactions, but nothing replaces real-world questions and close attention.
People who have their blood tested regularly, schedule check-ins, and keep a list of all drugs—prescription and otherwise—catch these problems sooner. Honest conversation with healthcare professionals lowers risk. Sharing your experience or any side effects right away can prevent hospital stays or more serious problems down the line.
Pregnancy brings excitement, anxiety, and a sharp focus on every pill and plate. Doctors get calls at all hours from expecting mothers caught between a diagnosis and the risk of treatment. Meprednisone, a corticosteroid used to control inflammation, sometimes lands at the center of these questions. As someone with years of covering women’s health, I’ve spoken to countless mothers who wonder if what helps their joints or skin could hurt their baby.
Steroid medications, meprednisone included, cross the placenta and make their way into breast milk. Most expecting mothers don’t have a chemistry set at home, so the path from swallowing a pill to sharing it with a developing child feels mysterious and worrisome. Science backs up these concerns. The American College of Obstetricians and Gynecologists tells us corticosteroids have a role in pregnancy, mostly for urgent problems like autoimmune flare-ups or fetal lung development. Yet, not every steroid works the same way, and not every stage of pregnancy reacts to the same dose.
Most safety data tracks close cousins of meprednisone, such as prednisone and prednisolone. Extensive studies say these drugs get prescribed with caution, always using the lowest dose for the shortest time. High doses for many weeks carry risks—think cleft palate, low birth weight, and infections later in childhood. Research on meprednisone itself sits somewhere in the shadow of its more famous relatives. Few large studies look only at meprednisone, so doctors fall back on evidence from similar drugs and expert opinion.
Corticosteroids don’t always mean a red light. Sometimes a flare of lupus or severe asthma threatens both mother and child far more than the medicine. Obstetricians will often consult with a mom’s other doctors before making a plan. Real-world practice shows most healthy babies arrive from mothers who took needed corticosteroids under supervision, but it’s rarely a decision made without stress.
After birth, another round of questions springs up. Is it safe to breastfeed while taking meprednisone? The facts help more here. Studies on prednisone and prednisolone say very little medicine gets into breast milk, especially if the dose stays at around 20 mg per day or less. Timing matters. Nursing right before taking the medication helps keep transfer to a minimum. With meprednisone’s close relation to these drugs, experienced pharmacists and pediatricians will often say the risk is low, especially for short-term use.
Still, every baby comes with a unique set of sensitivities, and mothers with high-dose requirements or premature newborns often need tailored advice. Each case involves weighing benefits against risks, not just for the mother’s comfort but for her ability to care for her newborn.
The world doesn’t work in absolutes. Trustworthy information helps parents and doctors make sense of hard choices. Reliable sources like the NIH’s LactMed database and organizations like MotherToBaby give evidence-based info on specific medicines and milk transfer. Experienced health providers, who know both the risks of the disease and the specifics of these drugs, create a roadmap most mothers can follow.
Questions about meprednisone remind us how much trust, science, and experience families invest in every decision. Each situation deserves a careful look, never a blanket answer. When treatments get weighed alongside hope, a clear conversation with a knowledgeable team matters most.
| Names | |
| Preferred IUPAC name | (11β)-17,21-Dihydroxy-6-methylpregna-1,4-diene-3,20-dione |
| Other names |
Meprednisolon
Mepid Medepred |
| Pronunciation | /ˌmiː.prɛdˈnɪz.oʊn/ |
| Preferred IUPAC name | (6α,11β,17α)-21-hydroxy-6-methylpregna-1,4-diene-3,11,20-trione |
| Other names |
Medred
Mepid Prednesol Promedrol |
| Pronunciation | /ˌmiː.prɛdˈnɪz.oʊn/ |
| Identifiers | |
| CAS Number | 2062-78-4 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Meprednisone**: ``` CC(=O)[C@]1(O)CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=CC4=CC(=O)CO[C@]34C)C ``` |
| Beilstein Reference | 2611049 |
| ChEBI | CHEBI:6727 |
| ChEMBL | CHEMBL1433 |
| ChemSpider | 65615 |
| DrugBank | DB00609 |
| ECHA InfoCard | 100.029.323 |
| EC Number | 3.2.1.34 |
| Gmelin Reference | 7148 |
| KEGG | D00477 |
| MeSH | D008597 |
| PubChem CID | 441422 |
| RTECS number | OM8225000 |
| UNII | 8U7X859222 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID2020179 |
| CAS Number | 1247-42-3 |
| Beilstein Reference | 84153 |
| ChEBI | CHEBI:6727 |
| ChEMBL | CHEMBL1433 |
| ChemSpider | 21106326 |
| DrugBank | DB00609 |
| ECHA InfoCard | 100.036.050 |
| EC Number | 1.1.1.215 |
| Gmelin Reference | 56959 |
| KEGG | D00473 |
| MeSH | D008592 |
| PubChem CID | 441336 |
| RTECS number | OM8225000 |
| UNII | Z8IX2SC11A |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID3020823 |
| Properties | |
| Chemical formula | C22H30O5 |
| Molar mass | 376.469 g/mol |
| Appearance | white or almost white, crystalline powder |
| Odor | Odorless |
| Density | 1.22 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 1.52 |
| Vapor pressure | <1.0E-6 hPa at 25 °C |
| Acidity (pKa) | 12.58 |
| Basicity (pKb) | 1.76 |
| Magnetic susceptibility (χ) | -7.1e-6 |
| Refractive index (nD) | 1.540 |
| Viscosity | Viscosity not provided |
| Dipole moment | 9.16 D |
| Chemical formula | C22H28O5 |
| Molar mass | 376.468 g/mol |
| Appearance | White or almost white, crystalline powder |
| Odor | Odorless |
| Density | 1.31 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 1.72 |
| Acidity (pKa) | 12.38 |
| Basicity (pKb) | 2.86 |
| Magnetic susceptibility (χ) | -84.5e-6 cm^3/mol |
| Refractive index (nD) | 1.581 |
| Viscosity | Viscosity not provided |
| Dipole moment | 2.56 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 372.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | −814.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6267 kJ/mol |
| Std molar entropy (S⦵298) | 324.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -6535 kJ/mol |
| Pharmacology | |
| ATC code | H02AB04 |
| ATC code | H02AB03 |
| Hazards | |
| Main hazards | May cause immunosuppression, increased susceptibility to infection, osteoporosis, adrenal suppression, hypertension, hyperglycemia, psychiatric disturbances, and gastrointestinal irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | Health hazard |
| Signal word | Warning |
| Hazard statements | Hazard statements: Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008. |
| Precautionary statements | P201, P202, P264, P270, P308+P313, P405, P501 |
| Flash point | 203.6°C |
| Lethal dose or concentration | Lethal dose or concentration of Meprednisone: "LD50 (oral, rat): 3250 mg/kg |
| LD50 (median dose) | LD50 (median dose): 3250 mg/kg (rat, oral) |
| NIOSH | RS-14790 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Meprednisone: Not established |
| REL (Recommended) | 40 mg |
| IDLH (Immediate danger) | NIOSH: Not Listed |
| Main hazards | Adrenal suppression, immunosuppression, increased risk of infection, osteoporosis, hyperglycemia, hypertension, psychiatric effects |
| GHS labelling | GHS labelling: "Not a hazardous substance or mixture according to the Globally Harmonized System (GHS) |
| Pictograms | GL, IN, OR |
| Signal word | No signal word |
| Hazard statements | Hazard statements: No known significant effects or critical hazards. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: |
| Flash point | 103.2°C |
| Explosive limits | Explosive limits: Non-explosive |
| Lethal dose or concentration | LD50 mouse oral 1650 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous 290 mg/kg |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | **16 mg** |
| Related compounds | |
| Related compounds |
Prednisone
Methylprednisolone Prednisolone |
| Related compounds |
Prednisone
Prednisolone Methylprednisolone Meprednisolone |
Providing high-quality chemical products and logistics solutions for global trade partners.
